ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer-Reference-Cited by-同舟云学术

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer

Published:2021-05 Issue:5 Volume:2 Page:503-514
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Deng Jiehui,Thennavan Aatish,Dolgalev Igor^ORCID,Chen Ting^ORCID,Li Jie^ORCID,Marzio Antonio,Poirier John T.^ORCID,Peng David H.,Bulatovic Mirna,Mukhopadhyay Subhadip,Silver Heather,Papadopoulos Eleni,Pyon Val,Thakurdin Cassandra,Han Han,Li Fei,Li Shuai,Ding Hailin,Hu Hai,Pan Yuanwang,Weerasekara Vajira,Jiang Baishan^ORCID,Wang Eric S.,Ahearn Ian,Philips Mark^ORCID,Papagiannakopoulos Thales,Tsirigos Aristotelis^ORCID,Rothenberg Eli^ORCID,Gainor Justin^ORCID,Freeman Gordon J.^ORCID,Rudin Charles M.^ORCID,Gray Nathanael S.^ORCID,Hammerman Peter S.,Pagano Michele^ORCID,Heymach John V.^ORCID,Perou Charles M.^ORCID,Bardeesy Nabeel^ORCID,Wong Kwok-Kin^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s43018-021-00208-6.pdf

Reference60 articles.

1. Skoulidis, F. et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822–835 (2018).

2. Kadara, H. et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann. Oncol. 28, 75–82 (2017).

3. Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin. Oncol. 36, 633–641 (2018).